{
  "source": "PA-Notification-Repository-Corticotropins.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1000-14\nProgram Prior Authorization/Notification\nMedication Repository Corticotropins - Acthar Gel® (repository corticotropin\ninjection), Purified Cortrophin Gel™ (repository corticotropin injection\nUSP)\nP&T Approval Date 5/2012, 4/2013, 2/2014, 5/2014, 5/2015, 4/2016, 4/2017, 4/2018,\n4/2019, 4/2020, 5/2021, 3/2022, 3/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nActhar Gel® (repository corticotropin injection) is an adrenocorticotropic hormone\n(ACTH) analogue US Food and Drug Administration (FDA) indicated for1:\n• Infantile Spasms: As monotherapy for the treatment of infantile spasms in infants\nand children under 2 years of age.\n• Multiple Sclerosis: For treatment of acute exacerbations of multiple sclerosis in\nadults.\nPer labeling, it is suggested that Acthar Gel may be used in the following conditions,\nhowever, it is not indicated for them1:\n• Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide\nthe patient over an acute episode or exacerbation) in psoriatic arthritis, rheumatoid\narthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose\nmaintenance therapy), and ankylosing spondylitis.\n• Collagen Diseases: During an exacerbation or as maintenance therapy in selected\ncases of systemic lupus erythematosus and systemic dermatomyositis (polymyositis).\n• Dermatologic Diseases: Severe erythema multiforme and Stevens-Johnson\nsyndrome.\n• Allergic States: Serum sickness.\n• Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes\ninvolving the eye and its adnexa such as: keratitis, iritis, iridocyclitis, diffuse\nposterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment\ninflammation.\n• Respiratory Diseases: Symptomatic sarcoidosis.\n• Edematous State: To induce a diuresis or a remission of proteinuria in the nephrotic\nsyndrome without uremia of the idiopathic type or that due to",
    "n.\n• Respiratory Diseases: Symptomatic sarcoidosis.\n• Edematous State: To induce a diuresis or a remission of proteinuria in the nephrotic\nsyndrome without uremia of the idiopathic type or that due to lupus erythematosus.\nPurified Cortrophin Gel™ (repository corticotropin injection USP) is an\nadrenocorticotropic hormone (ACTH) analogue indicated for2:\n• Rheumatic disorders: As adjunctive therapy for short-term administration (to tide\nthe patient over an acute episode or exacerbation) in psoriatic arthritis, rheumatoid\narthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose\nmaintenance therapy), ankylosing spondylitis, and acute gouty arthritis.\n• Collagen diseases: During an exacerbation or as maintenance therapy in selected\ncases of systemic lupus erythematosus and systemic dermatomyositis (polymyositis).\n• Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome)\nand severe psoriasis.\n© 2025 UnitedHealthcare Services, Inc.\n1\n• Allergic states: Atopic dermatitis and serum sickness.\n• Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes\ninvolving the eye and its adnexa such as allergic conjunctivitis, keratitis, iritis and\niridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis,\nand anterior segment inflammation.\n• Respiratory diseases: Symptomatic sarcoidosis.\n• Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic\nsyndrome without uremia of the idiopathic type or that due to lupus erythematosus.\n• Nervous system: Acute exacerbations of multiple sclerosis.\nAdditional evidence supports the use of repository corticotropin in opsoclonus-\nmyoclonus syndrome.3-5\nCoverage will be provided for members who meet the following criteria.\n2. Coverage Criteriaa:\nA. Infantile Spasms (i.e., West Syndrome)\n1. Initial Therapy\na. Acthar Gel and Purified Cortrophin Gel will be approved based on both of the\nfollowing criteria:\n(1) Diagnosis ",
    ".\n2. Coverage Criteriaa:\nA. Infantile Spasms (i.e., West Syndrome)\n1. Initial Therapy\na. Acthar Gel and Purified Cortrophin Gel will be approved based on both of the\nfollowing criteria:\n(1) Diagnosis of infantile spasms (West Syndrome)\n-AND-\n(2) Patient is less than 2 years of age\nAuthorization will be issued for 4 weeks.\n2. Reauthorization\nAll requests for reauthorization will be denied. All requests for continuation of therapy\nmust be submitted through the appeals process to the UnitedHealthcare Pharmacy\nappeals team for consideration.\nB. Multiple Sclerosis\n1. Initial Therapy\na. Acthar Gel and Purified Cortrophin Gel will be approved based on the following\ncriterion:\n(1) Diagnosis of acute exacerbation of multiple sclerosis\nAuthorization will be issued for 3 weeks.\n© 2025 UnitedHealthcare Services, Inc.\n2\n2. Reauthorization\na. Acthar Gel and Purified Cortrophin Gel will be approved based on the following\ncriterion:\n(1) Reauthorization request is for a new (different) episode of acute exacerbation of\nmultiple sclerosis\nAuthorization will be issued for 3 weeks.\nAll requests for reauthorization for treatment of the same exacerbation will be\ndenied. All requests for continuation of therapy for the same exacerbation must be\nsubmitted through the appeals process to the UnitedHealthcare Pharmacy appeals\nteam for consideration.\nC. Opsoclonus-Myoclonus Syndrome (i.e., Kinsbourne Syndrome) (off-label)\n1. Initial Authorization\na. Acthar Gel and Purified Cortrophin Gel will be approved based on the following\ncriteria:\n(1) Diagnosis of opsoclonus-myoclonus syndrome (Kinsbourne Syndrome)\nAuthorization will be issued for 3 months.\n2. Reauthorization\nAll requests for reauthorization will be denied. All requests for continuation of therapy\nmust be submitted through the appeals process to the UnitedHealthcare Pharmacy\nappeals team for consideration.\nD. Other Conditions:\n1. Initial Authorization\na. Purified Cortrophin Gel will be approved based on one the following criteria:\n(1) Rhe",
    " to the UnitedHealthcare Pharmacy\nappeals team for consideration.\nD. Other Conditions:\n1. Initial Authorization\na. Purified Cortrophin Gel will be approved based on one the following criteria:\n(1) Rheumatic disorders: As adjunctive therapy for short-term administration (to\ntide the patient over an acute episode or exacerbation) in psoriatic arthritis,\nrheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may\nrequire low-dose maintenance therapy), ankylosing spondylitis, or acute gouty\narthritis.\n-OR-\n(2) Collagen diseases: During an exacerbation or as maintenance therapy in selected\ncases of systemic lupus erythematosus or systemic dermatomyositis\n© 2025 UnitedHealthcare Services, Inc.\n3\n(polymyositis).\n-OR-\n(3) Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson\nsyndrome) or severe psoriasis.\n-OR-\n(4) Allergic states: Atopic dermatitis or serum sickness.\n-OR-\n(5) Ophthalmic diseases: Severe acute and chronic allergic and inflammatory\nprocesses involving the eye and its adnexa such as: Allergic conjunctivitis,\nkeratitis, iritis and iridocyclitis, diffuse posterior uveitis and choroiditis, optic\nneuritis, chorioretinitis, or anterior segment inflammation.\n-OR-\n(6) Respiratory diseases: Symptomatic sarcoidosis.\n-OR-\n(7) Edematous states: To induce a diuresis or a remission of proteinuria in the\nnephrotic syndrome without uremia of the idiopathic type or that due to lupus\nerythematosus.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Purified Cortrophin Gel will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Purified Cortrophin Gel therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealth",
    "c\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes\n(ICD-10) and/or claim logic. Use of automated approval and re-approval processes\nvaries by program and/or therapeutic class.\n• Supply limits and/or Step Therapy may be in place.\n© 2025 UnitedHealthcare Services, Inc.\n4\n4. References:\n1. Acthar Gel [package insert]. Bridgewater, NJ: Mallinckrodt ARD LLC.; February\n2024.\n2. Purified Cortrophin Gel [package insert]. Baudette, MN: ANI Pharmaceuticals, Inc.;\nDecember 2024.\n3. Pranzatelli MR, Huang YY, Tate E, et al. Monoaminergic effects of high-dose\ncorticotropin in corticotropin-responsive pediatric opsoclonus-myoclonus. Mov\nDisord. 1998;13(3):522-528.\n4. Pranzatelli MR, Chun KY, Moxness M, Tate ED, Allison TJ. Cerebrospinal fluid\nACTH and cortisol in opsoclonus-myoclonus: effect of therapy. Pediatr Neurol.\n2005;33(2):121-126.\n5. Tate ED, Pranzatelli MR, Verhulst SJ, et al. Active comparator-controlled, rater-\nblinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus\nsyndrome [published correction appears in J Child Neurol. 2012 Oct;27(10):1364.\nDosage error in article text]. J Child Neurol. 2012;27(7):875-884.\nProgram Prior Authorization/Notification - H.P. Acthar Gel (Repository\ncorticotropin injection)\nChange Control\n2/2014 Clarified reviewer designation for initial and reauthorization requests in\nCoverage Criteria.\n5/2014 Updated background and coverage criteria to only allow coverage for\nIS, MS and OMS.\n5/2015 Annual review with no change to clinical coverage.\n4/2016 Annual review with no change to clinical coverage. Updated\nreferences.\n4/2017 Annual review with no change to clinical coverage. Updated\nreferences.\n4/2018 Annual review with no change to clinical coverage. Updated\nreferenc",
    "hange to clinical coverage. Updated\nreferences.\n4/2017 Annual review with no change to clinical coverage. Updated\nreferences.\n4/2018 Annual review with no change to clinical coverage. Updated\nreferences.\n4/2019 Annual review with no change to clinical coverage. Updated reference.\n4/2020 Annual review with no change to clinical coverage. Updated reference.\n5/2021 Annual review with no change to clinical coverage. Updated reference.\n3/2022 Added Purified Cortrophin Gel to program. Updated program name,\nbackground and references.\n3/2023 Annual review with minor formatting updates to coverage criteria.\nAdded state mandate footnote and updated references.\n3/2024 Annual review with no changes to criteria. Updated references.\n3/2025 Annual review. Removed references to OptumRx throughout criteria\nwithout changes to intent of criteria. Updated background and\nreferences.\n© 2025 UnitedHealthcare Services, Inc.\n5"
  ]
}